Medartis Holding AG (SIX: MED) announced that shareholders at its 2026 Annual General Meeting (AGM) held on April 23, 2026, approved all substantive proposals from the Board of Directors with majorities exceeding 90.9%. The meeting, which took place at the company's headquarters in Basel, Switzerland, saw strong participation with 77.4% of total share capital represented, reflecting significant shareholder engagement.
Seven incumbent board members were re-elected with resounding support, each securing over 93.8% of votes represented. Notably, Yang Xu was newly elected to the Board of Directors with a 99.7% endorsement and will join the Finance and Audit Committee, bringing fresh expertise to the company's financial oversight. The board now comprises eight members, including Chairman Marco Gadola, Vice Chairman Dr. h.c. Thomas Straumann, and other seasoned directors across various committees.
Shareholders granted discharge to board members for their governance during the 2025 fiscal year and approved the maximum total remuneration for both the Board of Directors and the Executive Management Board, covering fixed and variable components. The 2025 management report and annual financial statements received near-unanimous approval at 99.99%, while the remuneration report was approved in a consultative vote with 91.0% support. The sustainability report garnered strong endorsement from 99.2% of represented shares, underscoring Medartis' commitment to transparent environmental, social, and governance (ESG) practices.
Key governance changes include the departure of Jennifer Dean, who decided not to stand for re-election after two years with Medartis. The assembly confirmed Damien Tappy and Marco Gadola as members of the Human Resources and Compensation Committee (HRCC), ensuring continuity in overseeing human capital strategy. The re-election of Neovius AG as independent voting representative and Ernst & Young AG as statutory auditors was also confirmed.
The strong shareholder approval signals confidence in Medartis' strategic direction under the leadership of Chairman Marco Gadola. The company, a global leader in medical devices for surgical fixation of bone fractures and joint replacement, continues to focus on innovation and service excellence. With manufacturing sites in Switzerland, the United States, Brazil, and France, and products offered in over 60 countries, Medartis employs approximately 1,400 individuals across 12 nations.
Looking ahead, Medartis confirmed key investor calendar dates: an Investor Visitor Day on June 4, 2026, in Basel during the FESSH Hand Surgery Congress, and the publication of first-half 2026 results on August 18, 2026, followed by an analyst and media briefing. The next Annual General Meeting is scheduled for April 22, 2027, at the company's headquarters.
For a detailed listing of all resolutions at the 2026 Annual General Meeting, please visit this link. Additional information about Medartis is available at www.medartis.com.
